On January 12, the U.S. Food and Drug Administration approved Lynparza (olaparib), the PARP inhibitor partnered by AstraZeneca and Merck, for the treatment of BRCA-mutated, HER2-negative advanced metastatic breast cancer. The FDA’s action adds another cancer type for Lynparza; in late 2014 it was the first PARP inhibitor to be approved for use in...